$AUTL
Autolus Therapeutics plc Stock $autl

$autl Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000173046323000110 Filed on November 09, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$0.00	$410.0K	$2.369M
YoY Change	-100.0%	-82.69%	903.81%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$15.73M	$10.61M	$8.231M
YoY Change	112.2%	28.9%	-0.82%
% of Gross Profit
Research & Development	$25.16M	$37.24M	$37.63M
YoY Change	-21.84%	-1.05%	16.54%
% of Gross Profit
Depreciation & Amortization	$1.775M	$1.400M	$1.787M
YoY Change	7.64%	-21.66%	-27.0%
% of Gross Profit
Operating Expenses	$40.89M	$37.24M	$45.86M
YoY Change	3.25%	-18.81%	12.99%
Operating Profit		-$47.82M	-$43.49M
YoY Change		9.96%
Interest Expense	-$24.52M	$5.014M	-$1.685M
YoY Change	10513.85%	-397.57%	-263.91%
% of Operating Profit
Other Income/Expense, Net	$594.0K	-$2.965M	-$3.740M
YoY Change	-86.66%	-20.72%	7532.65%
Pretax Income	-$64.81M	-$50.79M	-$48.92M
YoY Change	102.11%	3.82%	24.24%
Income Tax	$12.36M	-$4.940M	-$6.152M
% Of Pretax Income
Net Earnings	-$77.17M	-$45.85M	-$42.77M
YoY Change	186.34%	7.21%	25.82%
Net Earnings / Revenue		-11182.68%	-1805.28%
Basic Earnings Per Share		-$0.26	-$0.47
Diluted Earnings Per Share	-$0.44	-$0.26	-$468.7K
COMMON SHARES
Basic Shares Outstanding	174.0M shares	174.0M shares	91.24M shares
Diluted Shares Outstanding		174.0M shares	91.24M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$239.6M	$256.4M	$163.1M
YoY Change	-37.36%	57.25%	-5.78%
Cash & Equivalents	$239.6M	$256.4M	$163.1M
Short-Term Investments
Other Short-Term Assets	$11.19M	$127.0K	$49.26M
YoY Change	5414.29%	-99.74%	377.95%
Inventory
Prepaid Expenses	$8.638M	$7.535M
Receivables	$109.0K	$165.0K	$2.088M
Other Receivables	$24.43M	$2.357M	$39.19M
Total Short-Term Assets	$275.3M	$308.4M	$212.3M
YoY Change	-35.34%	45.25%	-10.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$34.86M	$34.64M	$45.71M
YoY Change	-0.99%	-24.22%	-14.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.426M	$3.700M	$5.802M
YoY Change	-27.25%	-36.23%	1.54%
Total Long-Term Assets	$100.1M	$97.72M	$51.52M
YoY Change	55.15%	89.67%	-12.62%
TOTAL ASSETS
Total Short-Term Assets	$275.3M	$308.4M	$212.3M
Total Long-Term Assets	$100.1M	$97.72M	$51.52M
Total Assets	$375.4M	$406.1M	$263.8M
YoY Change	-23.43%	53.92%	-11.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$103.0K	$661.0K	$334.0K
YoY Change	-80.6%	97.9%	-77.15%
Accrued Expenses	$39.58M	$31.39M	$38.48M
YoY Change	-2.98%	-18.44%	17.39%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$44.74M	$37.54M	$38.82M
YoY Change	-3.51%	-3.29%	12.31%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$357.0K	$295.0K	$63.86M
YoY Change	207.76%	-99.54%	268.21%
Total Long-Term Liabilities	$357.0K	$295.0K	$63.86M
YoY Change	207.76%	-99.54%	268.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$44.74M	$37.54M	$38.82M
Total Long-Term Liabilities	$357.0K	$295.0K	$63.86M
Total Liabilities	$263.9M	$225.6M	$102.7M
YoY Change	37.74%	119.7%	97.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$878.6M	-$801.4M	-$643.2M
YoY Change	31.09%	24.59%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$111.5M	$180.5M	$161.2M
YoY Change
Total Liabilities & Shareholders Equity	$375.4M	$406.1M	$263.8M
YoY Change	-23.43%	53.92%	-11.06%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$77.17M	-$45.85M	-$42.77M
YoY Change	186.34%	7.21%	25.82%
Depreciation, Depletion And Amortization	$1.775M	$1.400M	$1.787M
YoY Change	7.64%	-21.66%	-27.0%
Cash From Operating Activities	-$24.83M	-$40.18M	-$31.90M
YoY Change	70.49%	25.94%	-8.19%
INVESTING ACTIVITIES
Capital Expenditures	$1.477M	$1.500M	$6.797M
YoY Change	133.33%	-77.93%	-276.04%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$1.477M	-$1.500M	-$6.797M
YoY Change	133.33%	-77.93%	76.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	23.00K	0.000	102.0K
YoY Change	-99.99%	-100.0%	-144.35%
NET CHANGE
Cash From Operating Activities	-24.83M	-40.18M	-31.90M
Cash From Investing Activities	-1.477M	-1.500M	-6.797M
Cash From Financing Activities	23.00K	0.000	102.0K
Net Change In Cash	-26.29M	-41.68M	-38.60M
YoY Change	-112.62%	7.98%	-0.62%
FREE CASH FLOW
Cash From Operating Activities	-$24.83M	-$40.18M	-$31.90M
Capital Expenditures	$1.477M	$1.500M	$6.797M
Free Cash Flow	-$26.31M	-$41.68M	-$38.70M
YoY Change	73.1%	7.7%	25.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001730463
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Security12b Title Security12bTitle	American Depositary Shares, each representing one ordinary share, par value $0.000042 per share
	dei	Trading Symbol TradingSymbol	AUTL
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	173989157	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	256415000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	382436000	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	434000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	325000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	51533000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	43010000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	308382000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	425771000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34637000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35209000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	136000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2176000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	59403000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23210000	usd
CY2023Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2597000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2076000	usd
CY2023Q3	us-gaap	Assets Assets	406098000	usd
CY2022Q4	us-gaap	Assets Assets	490274000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	661000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	531000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31388000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	40797000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5491000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5038000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	37540000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	46366000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	46967000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19218000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	140778000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	125900000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	295000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	116000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	225580000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	191600000	usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1015577000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1007625000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-33794000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-38898000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-801391000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-670179000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	180518000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	298674000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	406098000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	490274000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	105323000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	109806000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31017000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24487000	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-3791000	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	382000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-138815000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-131758000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-333000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4214000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	5014000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	1850000	usd
	us-gaap	Interest Expense InterestExpense	14939000	usd
	us-gaap	Interest Expense InterestExpense	5448000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.75
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	229336000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2864000	usd
CY2023Q3	autl	Stock Vested During Period Value Restricted Stock StockVestedDuringPeriodValueRestrictedStock	0	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-5837000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-45849000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	180518000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	214521000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3337000	usd
CY2022Q3	autl	Stock Vested During Period Value Restricted Stock StockVestedDuringPeriodValueRestrictedStock	0	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	117000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-14054000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-42767000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	161154000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	298674000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7948000	usd
	autl	Stock Vested During Period Value Restricted Stock StockVestedDuringPeriodValueRestrictedStock	0	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5104000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-131212000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	180518000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	313320000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8599000	usd
	autl	Stock Vested During Period Value Restricted Stock StockVestedDuringPeriodValueRestrictedStock	0	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	117000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-38994000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-121888000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	161154000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-131212000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-121888000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4790000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5773000	usd
	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	7929000	usd
	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	8599000	usd
	autl	Collaboration Agreement Non Cash Interest Expense CollaborationAgreementNonCashInterestExpense	14878000	usd
	autl	Collaboration Agreement Non Cash Interest Expense CollaborationAgreementNonCashInterestExpense	5427000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	366000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-10537000	usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-95000	usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-3812000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	382000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	0	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	520000	usd
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	587000	usd
	autl	Increase Decrease In Prepaid Expense And Other Assets Current IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent	7655000	usd
	autl	Increase Decrease In Prepaid Expense And Other Assets Current IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent	20809000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1932000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-301000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-937000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	5000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	69000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-87000	usd
	autl	Increase Decrease In Accrued Liabilities Lease Liability And Other Liabilities IncreaseDecreaseInAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities	-6823000	usd
	autl	Increase Decrease In Accrued Liabilities Lease Liability And Other Liabilities IncreaseDecreaseInAccruedLiabilitiesLeaseLiabilityAndOtherLiabilities	15469000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-9002000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-472000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-120754000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-97742000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9509000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10208000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9509000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10208000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	117000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	910000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	16000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-906000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-801400000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-670200000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	101000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5257000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-39459000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-125912000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-147308000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	382761000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	310676000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	256849000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	163368000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1389000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1219000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	41211000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	57000	usd
	autl	Right Of Use Asset Terminated And Obtained In Exchange For Operating Lease Liability RightOfUseAssetTerminatedAndObtainedInExchangeForOperatingLeaseLiability	-1110000	usd
	autl	Right Of Use Asset Terminated And Obtained In Exchange For Operating Lease Liability RightOfUseAssetTerminatedAndObtainedInExchangeForOperatingLeaseLiability	0	usd
	autl	Hosting Arrangement Service Contract Implementation Cost Capitalized After Accumulated Amortization Current And Noncurrent HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent	74000	usd
	autl	Hosting Arrangement Service Contract Implementation Cost Capitalized After Accumulated Amortization Current And Noncurrent HostingArrangementServiceContractImplementationCostCapitalizedAfterAccumulatedAmortizationCurrentAndNoncurrent	31000	usd
	autl	Capitalized Sharebased Compensation CapitalizedSharebasedCompensation	19000	usd
	autl	Capitalized Sharebased Compensation CapitalizedSharebasedCompensation	0	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	256415000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	163053000	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	434000	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	315000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	256849000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	163368000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Nature of the Business<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autolus Therapeutics plc (the “Company”) is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer and autoimmune diseases. Using its broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and attack and kill these cells. The Company believes its programmed T cell therapies have the potential to be best-in-class and to offer cancer patients substantial benefits over the existing standard of care, including the potential for cure in some patients.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including precl</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from its product sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has funded its operations primarily with proceeds from the sale of equity securities through public offerings and sales pursuant to the Company's at-the-market facility, government grants, U.K. research and development tax credits and receipts from the U.K.'s Research and Development Expenditure Credit program ("RDEC"), out-licensing arrangements and strategic collaboration agreements.</span></div>
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-45800000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-42800000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-131200000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-121900000	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1700000	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3800000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-400000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4400000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Lease Term—Impact on Right-of-Use Assets and Lease Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into an arrangement for lease with Forge Life Sciences Nominee, an affiliate of the Reef Group, for the design, construction and lease of the Company's new 70,000 square foot commercial manufacturing facility, referred to as, The Nucleus, in Stevenage, United Kingdom. Under this arrangement, the landlord leased the facility to the Company on agreed terms, upon satisfaction of certain conditions and completion of construction. Since November 2022, the landlord has handed over various portions of the facility to the Company until July 31, 2023 when the landlord and the Company accepted practical completion of The Nucleus. The Company was required to pay a pro-rated license fee for each portion of the facility which the Company has been granted access until execution of the lease agreement. As the landlord provided the Company with access to portions of the facility, the definition of a lease in accordance with ASC 842, was met. The lease term can materially impact the value of the right of use assets and lease liabilities recorded on our balance sheet as required under ASC 842.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 19, 2023, the Company entered into a 20 year lease agreement with Forge Life Sciences Nominee for The Nucleus. The Company calculated the lease term for The Nucleus by taking into account, the noncancellable period specified in the agreement together with the periods a license fee was payable by the Company to the landlord for portions of The Nucleus handed over to the Company.</span></div>
CY2023Q3	autl	Number Of Distinct Performance Obligations NumberOfDistinctPerformanceObligations	1	performanceobligation
CY2023Q3	autl	Research And Development Claims Receivable Current ResearchAndDevelopmentClaimsReceivableCurrent	37111000	usd
CY2022Q4	autl	Research And Development Claims Receivable Current ResearchAndDevelopmentClaimsReceivableCurrent	24685000	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7535000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	12337000	usd
CY2023Q3	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	2327000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	2701000	usd
CY2023Q3	us-gaap	Deferred Costs Current DeferredCostsCurrent	1911000	usd
CY2022Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	1494000	usd
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent	127000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	203000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	165000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	121000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	51533000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	43010000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	29017000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	27542000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	34637000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35209000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	1400000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	1800000	usd
	us-gaap	Depreciation Depreciation	4800000	usd
	us-gaap	Depreciation Depreciation	5700000	usd
CY2023Q3	autl	Accrued Research And Development Cost Current AccruedResearchAndDevelopmentCostCurrent	17863000	usd
CY2022Q4	autl	Accrued Research And Development Cost Current AccruedResearchAndDevelopmentCostCurrent	26478000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10169000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10181000	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2873000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3745000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	483000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	393000	usd
CY2023Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	31388000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	40797000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2864000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3337000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7948000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8599000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-45849000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-42767000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-131212000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-121888000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-45849000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-45849000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42767000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-42767000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-131212000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-131212000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-121888000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-121888000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	173984101	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	173984101	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91240801	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91240801	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	173890666	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	173890666	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91028562	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91028562	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.75
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.75
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.34
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17604474	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17604474	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14683370	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14683370	shares
CY2022Q4	autl	Number Of Development Payments NumberOfDevelopmentPayments	2	payment
CY2023Q3	autl	Collaboration Agreement Non Cash Interest Expense CollaborationAgreementNonCashInterestExpense	5000000.0	usd
CY2022Q3	autl	Collaboration Agreement Non Cash Interest Expense CollaborationAgreementNonCashInterestExpense	1800000	usd
	autl	Collaboration Agreement Non Cash Interest Expense CollaborationAgreementNonCashInterestExpense	14900000	usd
	autl	Collaboration Agreement Non Cash Interest Expense CollaborationAgreementNonCashInterestExpense	5400000	usd
CY2023Q3	autl	Number Of Manufacturing Suites With Extended Lease Term NumberOfManufacturingSuitesWithExtendedLeaseTerm	1	manufacturingsuite
CY2021Q1	autl	Number Of Real Estate Units Split NumberOfRealEstateUnitsSplit	1	unit
CY2021Q1	autl	Number Of Real Estate Units After Split Of A Unit NumberOfRealEstateUnitsAfterSplitOfAUnit	2	unit
	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	7500000	usd
CY2023Q3	us-gaap	Asset Retirement Obligation AssetRetirementObligation	100000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	2061000	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	1103000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	5235000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	3542000	usd
CY2023Q3	autl	Variable Lease Cost Net Of Reversal VariableLeaseCostNetOfReversal	573000	usd
CY2022Q3	autl	Variable Lease Cost Net Of Reversal VariableLeaseCostNetOfReversal	268000	usd
	autl	Variable Lease Cost Net Of Reversal VariableLeaseCostNetOfReversal	657000	usd
	autl	Variable Lease Cost Net Of Reversal VariableLeaseCostNetOfReversal	720000	usd
CY2023Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	227000	usd
CY2022Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	119000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	451000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	231000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	2861000	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	1490000	usd
	us-gaap	Lease Cost LeaseCost	6343000	usd
	us-gaap	Lease Cost LeaseCost	4493000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	7817000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	3740000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P15Y10M24D
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0744
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0718
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1975000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8062000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6625000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6396000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6255000	usd
CY2023Q3	autl	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	60424000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	89737000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	37279000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	52458000	usd
CY2021Q4	autl	Lessor Operating Lease Number Of Contracts LessorOperatingLeaseNumberOfContracts	2	contract
CY2021Q4	autl	Lessor Operating Lease Number Of Third Parties LessorOperatingLeaseNumberOfThirdParties	2	thirdparty
CY2021Q4	autl	Lessor Operating Lease Number Of Manufacturing Properties LessorOperatingLeaseNumberOfManufacturingProperties	2	contract
CY2021Q4	us-gaap	Proceeds From Deposits From Customers ProceedsFromDepositsFromCustomers	100000	usd
CY2023Q3	us-gaap	Sublease Income SubleaseIncome	61000	usd
CY2022Q3	us-gaap	Sublease Income SubleaseIncome	57000	usd
	us-gaap	Sublease Income SubleaseIncome	181000	usd
	us-gaap	Sublease Income SubleaseIncome	183000	usd
CY2023Q3	us-gaap	Sublease Income SubleaseIncome	61000	usd
CY2022Q3	us-gaap	Sublease Income SubleaseIncome	57000	usd
	us-gaap	Sublease Income SubleaseIncome	181000	usd
	us-gaap	Sublease Income SubleaseIncome	183000	usd
CY2023Q3	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	65000	usd
CY2023Q3	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	261000	usd
CY2023Q3	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	261000	usd
CY2023Q3	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	203000	usd
CY2023Q3	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	123000	usd
CY2023Q3	autl	Lessor Operating Lease Payment To Be Received After Year Four LessorOperatingLeasePaymentToBeReceivedAfterYearFour	106000	usd
CY2023Q3	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	1019000	usd
CY2023Q3	autl	Collaborative Arrangement Rights And Obligations Payments Payable CollaborativeArrangementRightsAndObligationsPaymentsPayable	100000	usd
	autl	Collaborative Arrangement Rights And Obligations Payments Payable CollaborativeArrangementRightsAndObligationsPaymentsPayable	200000	usd
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2023Q3	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2023Q3	us-gaap	Unrecorded Unconditional Purchase Obligation Balance Sheet Amount UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount	4200000	usd
CY2021Q4	autl	Number Of Directors NumberOfDirectors	1	contract
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	140800000	usd
	autl	Contract With Customer Liability Accrued Interest ContractWithCustomerLiabilityAccruedInterest	24900000	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	56500000	shares
CY2023Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	113000000.0	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1700000	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3800000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-400000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-4400000	usd

Files In Submission

Name	View Source	Status
autl-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001730463-23-000110-index-headers.html	Edgar Link	pending
0001730463-23-000110-index.html	Edgar Link	pending
0001730463-23-000110.txt	Edgar Link	pending
0001730463-23-000110-xbrl.zip	Edgar Link	pending
autl-20230930.htm	Edgar Link	pending
autl-20230930.xsd	Edgar Link	pending
autl-20230930_def.xml	Edgar Link	unprocessable
autl-20230930_lab.xml	Edgar Link	unprocessable
autl-20230930_htm.xml	Edgar Link	completed
autolus-10xqx30092023ex311.htm	Edgar Link	pending
autolus-10xqx30092023ex312.htm	Edgar Link	pending
autolus-10xqx30092023ex321.htm	Edgar Link	pending
exhibit101-nucleusleased.htm	Edgar Link	pending
exhibit101-nucleusleased001.jpg	Edgar Link	pending
exhibit101-nucleusleased002.jpg	Edgar Link	pending
exhibit101-nucleusleased003.jpg	Edgar Link	pending
exhibit101-nucleusleased004.jpg	Edgar Link	pending
exhibit101-nucleusleased005.jpg	Edgar Link	pending
exhibit101-nucleusleased006.jpg	Edgar Link	pending
exhibit101-nucleusleased007.jpg	Edgar Link	pending
exhibit101-nucleusleased008.jpg	Edgar Link	pending
exhibit101-nucleusleased009.jpg	Edgar Link	pending
exhibit101-nucleusleased010.jpg	Edgar Link	pending
exhibit101-nucleusleased011.jpg	Edgar Link	pending
exhibit101-nucleusleased012.jpg	Edgar Link	pending
exhibit101-nucleusleased013.jpg	Edgar Link	pending
exhibit101-nucleusleased014.jpg	Edgar Link	pending
exhibit101-nucleusleased015.jpg	Edgar Link	pending
exhibit101-nucleusleased016.jpg	Edgar Link	pending
exhibit101-nucleusleased017.jpg	Edgar Link	pending
exhibit101-nucleusleased018.jpg	Edgar Link	pending
exhibit101-nucleusleased019.jpg	Edgar Link	pending
exhibit101-nucleusleased020.jpg	Edgar Link	pending
exhibit101-nucleusleased021.jpg	Edgar Link	pending
exhibit101-nucleusleased022.jpg	Edgar Link	pending
exhibit101-nucleusleased023.jpg	Edgar Link	pending
exhibit101-nucleusleased024.jpg	Edgar Link	pending
exhibit101-nucleusleased025.jpg	Edgar Link	pending
exhibit101-nucleusleased026.jpg	Edgar Link	pending
exhibit101-nucleusleased027.jpg	Edgar Link	pending
exhibit101-nucleusleased028.jpg	Edgar Link	pending
exhibit101-nucleusleased029.jpg	Edgar Link	pending
exhibit101-nucleusleased030.jpg	Edgar Link	pending
exhibit101-nucleusleased031.jpg	Edgar Link	pending
exhibit101-nucleusleased032.jpg	Edgar Link	pending
exhibit101-nucleusleased033.jpg	Edgar Link	pending
exhibit101-nucleusleased034.jpg	Edgar Link	pending
exhibit101-nucleusleased035.jpg	Edgar Link	pending
exhibit101-nucleusleased036.jpg	Edgar Link	pending
exhibit101-nucleusleased037.jpg	Edgar Link	pending
exhibit102-amendment2tos.htm	Edgar Link	pending
exhibit102-amendment2tos001.jpg	Edgar Link	pending
exhibit102-amendment2tos002.jpg	Edgar Link	pending
exhibit102-amendment2tos003.jpg	Edgar Link	pending
exhibit102-amendment2tos004.jpg	Edgar Link	pending
exhibit102-amendment2tos005.jpg	Edgar Link	pending
exhibit102-amendment2tos006.jpg	Edgar Link	pending
exhibit102-amendment2tos007.jpg	Edgar Link	pending
exhibit102-amendment2tos008.jpg	Edgar Link	pending
exhibit102-amendment2tos009.jpg	Edgar Link	pending
exhibit102-amendment2tos010.jpg	Edgar Link	pending
exhibit102-amendment2tos011.jpg	Edgar Link	pending
exhibit102-amendment2tos012.jpg	Edgar Link	pending
exhibit102-amendment2tos013.jpg	Edgar Link	pending
exhibit102-amendment2tos014.jpg	Edgar Link	pending
exhibit102-amendment2tos015.jpg	Edgar Link	pending
exhibit102-amendment2tos016.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
autl-20230930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AUTL
Autolus Therapeutics plc Stock $autl

2023 Q4 Form 10-Q Financial Statement

#000173046323000110 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUTL Autolus Therapeutics plc Stock $autl

2023 Q4 Form 10-Q Financial Statement

#000173046323000110 Filed on November 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUTL
Autolus Therapeutics plc Stock $autl